PharmAust raises cash for anti-cancer study
Clinical stage biotechnology company PharmAust has received commitments to raise $10 million via an institutional placement with directors and management subscribing for $1 million worth of shares. The cash will be used to finalise preparations for an adaptive Phase 2/3 STRIKE study in patients with Motor Neurone Disease (MND) of the drug monepantel. Monepantel is…